2-47478353-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.2292G>A(p.Trp764*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.W764* pathogenic mutation (also known as c.2292G>A), located in coding exon 14 of the MSH2 gene, results from a G to A substitution at nucleotide position 2292. This changes the amino acid from a tryptophan to a stop codon within coding exon 14. This mutation, designated as p.W764X, has been reported in patients from various ethnicities who meet Amsterdam criteria (Czakó L et al. Orv Hetil, 2005 May;146:1009-16; Spaepen M et al. Fam Cancer, 2006;5:179-89; Wang XL et al. World J Gastroenterol, 2006 Jul;12:4074-7). A similar alteration (c.2291G>A) resulting in the same premature stop codon (designated p.Trp764X) as been reported in an individual with the Muir-Torre variant of Lynch syndrome whose colorectal cancer and hepatocellular carcinoma both demonstrated high microsatellite instability and MSH2-/MSH6- by IHC (Casper M et al. Scand J Gastroenterol, 2013 Mar;48:344-51). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
This variant changes 1 nucleotide in exon 14 of the MSH2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has been reported in individuals affected with Lynch syndrome (PMID: 15945244, 16736289, 16810763). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Lynch syndrome Pathogenic:1
Coding sequence variation introducing premature termination codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Trp764*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 15945244, 16736289, 16810763). ClinVar contains an entry for this variant (Variation ID: 90949). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at